The Clinical Efficacy of Intravesical Botox Injections When Combined With HoLEP Surgery in Patients With Benign Prostatic Hyperplasia and Overactive Bladder

Benign prostatic hyperplasia (BPH) is the most common benign neoplasm in men. Almost 90% of men in their 70s report lower urinary tract symptoms related to BPH. These symptoms carry a significant negative impact on the patients' quality of life.
Despite the wide availability of surgical offerings to relieve bladder outlet obstruction such as transurethral resection of the prostate (TURP), Holmium Laser Enucleation of the Prostate (HoLEP), and prostatectomy, many patients still suffer from persistent LUTS after undergoing these. A study describing postoperative outcomes following HoLEP revealed that patients with severe lower urinary tract symptoms, storage-positive sub-score, and high maximum urinary flow rate before the surgery were affected by a rebound of mainly storage symptoms 6-8 weeks after HoLEP and prolonged recovery from LUTS with 7.4% of them presenting for persistent urge complaints.
Optimizing the management approach for these patients has been limited by lack of high level evidence-based recommendations and expert consensus. Intravesical botox injections are well-established therapeutic options for several urinary disorders. The current practice offers intravesical botox injections to patients who suffer from persistent urinary symptoms few months after their BPH procedure. This study aims to evaluate if giving botox injections at the time of the HoLEP surgery would yield a better outcome than performing the two procedures separately at different times (few months apart).
The concomitant use of botox injection during bladder de-obstructing procedures has been previously studied in TURP and have showed a significant reduction of incontinence episodes and OAB symptoms in the group that were treated with botox injections after 36 weeks post TURP. This data may suggest promising potential of this intervention in managing persistent OAB symptoms in patients with BOO. However, the efficacy of combining HoLEP and bladder Botox injections has not been systematically studied and evaluated.
The aim of this study is to evaluate the effect of intravesical Botox injections on lower urinary tract symptoms (LUTS) when administered during HoLEP surgery in patients with bladder outlet obstruction (BOO) and overactive bladder symptoms (OAB). The investigators are interested in comparing the postoperative outcome in terms of recovery and symptom relief in patients who performed HoLEP surgery with bladder Botox injections versus those who performed HoLEP surgery only at 2 weeks,1 month, 3 months, and 6 months postoperatively.
The investigators hypothesize that administering bladder botox injections during HoLEP surgery is a combination treatment that will result in faster and more potent symptom relief compared to patients who received only a HoLEP surgery for their obstructive and irritative symptoms.

开始日期2026-06-01

申办/合作机构

University Hospitals Cleveland Medical Center

NCT07082972

/ Recruiting临床4期IIT

Evaluation of the Effects of Occlusal Splint and Masseter Botulinum Toxin Injections on Head and Neck Muscles Using Electromyography

This randomized controlled clinical trial aims to evaluate the individual and combined effects of occlusal splint therapy and botulinum toxin type A (BTX-A) injections into the masseter muscle on the activity of head and neck muscles in patients diagnosed with myofascial pain syndrome (MPS). MPS is a common subtype of temporomandibular disorders (TMD), frequently involving the masticatory and cervical muscles. Despite various treatment modalities, there is still no universally accepted protocol. In this study, 56 adult participants of both sexes, without missing teeth and within a normal body mass index (BMI) range, will be randomly assigned to four groups: BTX-A injection only, occlusal splint only, combined BTX-A and splint therapy, and an untreated control group. Surface electromyography (EMG) will be used to assess muscle activity in the masseter, temporalis, sternocleidomastoid, splenius capitis, and trapezius muscles. EMG recordings will be performed at baseline, 4 weeks, and 12 weeks after the intervention. Pain levels and symptom severity will be assessed using the DC/TMD symptom questionnaire and the Visual Analog Scale (VAS). BTX-A injections will be administered by a neurology specialist (20 IU per masseter muscle), and occlusal splints will be custom-fabricated and fitted for each participant. This study seeks to determine the neuromuscular effects of these treatments-both alone and in combination-on masticatory and cervical muscles and to provide insight into the development of more comprehensive and effective treatment strategies for MPS.

开始日期2025-09-01

申办/合作机构

Istanbul University

NCT07025642

/ RecruitingN/AIIT

Outcome of Different Treatments of Overactive Bladder in Taiwan

Overactive bladder (OAB) syndrome is a prevalent condition that significantly impairs patients' quality of life. Standard therapeutic strategies include oral antimuscarinics (e.g., solifenacin), beta-3 adrenergic agonists (e.g., mirabegron), and intradetrusor injection of botulinum neurotoxin type A (BoNTA). Despite their clinical utility, these treatments share a common mechanism of action: suppression of detrusor muscle contractility. However, it remains unclear whether such suppression translates to a reduction in the overall mechanical work output of the bladder during micturition.
To address this question, our research proposes to assess how mirabegron, solifenacin, and BoNTA influence bladder function from a thermodynamic perspective. We will apply pressure-volume analysis (PVA), a methodology traditionally used in cardiac physiology, to quantify the mechanical work performed by the bladder per voiding cycle. This approach enables a direct measurement of the energy expenditure required for bladder emptying, offering insights beyond standard urodynamic parameters.
Furthermore, emerging data suggest BoNTA may exert additional effects beyond parasympathetic inhibition. Specifically, recent studies have demonstrated that BoNTA also inhibits norepinephrine release from sympathetic hypogastric nerve terminals. Since modulation of sympathetic activity-particularly via the hypogastric nerve-has been implicated in regulating bladder compliance and storage function, we hypothesize that BoNTA may influence bladder compliance through this secondary mechanism. To explore this, we will employ volume-pressure analysis (also abbreviated as PVA), which graphically represents the dynamic relationship between bladder volume and pressure throughout voiding cycles, thus capturing real-time changes in compliance.
Comparative studies of mirabegron, solifenacin, and BoNTA will allow us to differentiate their respective impacts on bladder work and compliance. Mirabegron, which selectively activates beta-3 adrenergic receptors, has minimal influence on overall sympathetic tone. In contrast, solifenacin not only antagonizes muscarinic receptors but may also indirectly potentiate sympathetic tone by reducing parasympathetic influence. BoNTA, with its dual action on both autonomic pathways, provides a unique model to dissect these neural mechanisms.
To extend our findings from clinical observations to preclinical validation, we aim to develop and utilize a spinal cord injury (SCI) rat model that recapitulates the bladder dysfunction observed in neurogenic detrusor overactivity (NDO)-a condition for which mirabegron, solifenacin, and BoNTA are also commonly prescribed. By applying both thermodynamic and compliance-focused PVA techniques in this animal model, we seek to construct a foundational database characterizing how these drugs modulate bladder function in a controlled, reproducible setting.
In summary, this project integrates a novel application of pressure- and volume-based analyses to quantify the mechanical and compliance-related effects of established OAB therapies in both human patients and a translational animal model. The findings will provide new mechanistic insights into how these treatments alter bladder physiology, potentially guiding future therapeutic strategies and optimizing drug selection for individualized patient care.

开始日期2025-07-01

申办/合作机构

Mackay Medical College

100 项与 A型肉毒毒素相关的临床结果

登录后查看更多信息

100 项与 A型肉毒毒素相关的转化医学

登录后查看更多信息

100 项与 A型肉毒毒素相关的专利（医药）

登录后查看更多信息

5,326

项与 A型肉毒毒素相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

Systematic review of pharmacotherapy for atypical facial pain: evaluation of pain reduction, depression, anxiety and quality of life

Review

作者: Alshammari, Sattam S. ; Alassaf, Hind M. ; Alqarni, Ali A. ; Abed, Hassan H. ; Shaikh, Sameer ; Alkurdi, Khlood A. ; Alshammari, Abdullah F. ; Alshammary, Freah L. ; Madfa, Ahmed A.

BACKGROUND/PURPOSE:

Atypical facial pain (AFP) is a chronic condition characterized by persistent facial pain without clear clinical signs, making diagnosis and treatment difficult. Common pharmacological treatments include antidepressants, anticonvulsants and neuromodulators, but their effectiveness remains uncertain, necessitating a systematic review to guide clinical practice.

MATERIALS AND METHODS:

Following PRISMA 2020 guidelines, randomized controlled trials (RCTs) evaluating pharmacological treatments for AFP in adults were included. A comprehensive search of five databases without date restrictions was performed. Data on pain reduction, quality of life, and adverse events were extracted. The Cochrane Risk of Bias (RoB 2.0) tool assessed bias, and evidence quality was evaluated using the Critical Appraisal Skills Programme tool.

RESULTS:

Out of 196 studies identified, 10 RCTs met the inclusion criteria. Pharmacological responses varied significantly across studies. Antidepressants such as dothiepin and clomipramine demonstrated significant pain reduction, whereas venlafaxine showed limited efficacy. However, onabotulinum toxin A and sumatriptan exhibited inconsistent or minimal effects on AFP pain intensity. Adverse events were reported across multiple treatments, ranging from mild side effects such as dry mouth and nausea to severe reactions like diplopia and facial asymmetry, which impacted adherence. Despite some positive outcomes, the heterogeneity in study methodologies, outcome measures, and follow-up durations limited direct comparisons between interventions.

CONCLUSION:

This systematic review highlights the mixed efficacy of pharmacological treatments for AFP, with certain medications demonstrating superior pain relief in specific patient subgroups. Given the variability in response and adverse events, a multimodal approach combining pharmacological and non-pharmacological therapies may offer the most effective management strategy. Future research should focus on standardized treatment protocols, long-term efficacy, and personalized treatment plans to optimize patient care.

2025-12-01·Techniques in Coloproctology

Management of chronic anal fissures: should fissurectomy be performed with botulinum toxin injection?

Article

作者: Albayati, S ; Ellis-Clark, J ; Quinn, R

Abstract:

Background:

Despite the superior success rate of lateral internal sphincterotomy for managing chronic anal fissure (CAF), there is a trend towards sphincter-preserving treatment due to the increased risk of incontinence. Botulinum toxin (BT) and fissurectomy are two sphincter-preserving options for CAF. We aim to assess if combining fissurectomy with botox treatment is superior to botulinum toxin alone in the management of CAF.

Methods:

This retrospective cohort study was conducted across two Sydney hospitals over 7 years. All patients with a CAF managed with either BT and fissurectomy (group 1) or BT only (group 2) were included. Primary outcome was healing rate defined as resolution or significant improvement of perianal symptoms at initial follow-up. Secondary outcomes were persistence, recurrence, re-intervention and faecal incontinence rate. Follow-up questionnaire was conducted to compare long-term outcomes between the two groups.

Results:

Fifty-seven patients met the inclusion criteria (group 1, 37; group 2, 20). Mean BT dose and injection location between the groups were similar (p = 0.259 and p = 0.427). There was a 65% response rate to the follow-up questionnaire. Median follow-up was 34.3 months (range 0.4–93). There was no difference in healing (56.7% vs. 50%, p = 0.561), recurrence (37.8% vs. 30%, p = 0.383) or re-intervention rate (13.5% vs. 20%, p = 0.888). Long-term incontinence rate was significantly higher in patients group 2 (0% vs. 10%, p = 0.010), with two patients reporting persistent flatus incontinence. Median overall satisfaction score was 3/4 (range 1–4), in both groups (p = 0.469).

Conclusion:

Botulinum toxin with or without fissurectomy is a safe sphincter-sparing treatment option for CAF. However, the addition of fissurectomy to BT does not improve healing rates and we therefore recommend BT injection alone as a second-line treatment of CAF in patients who fail topical treatment.

2025-12-01·Current Pain and Headache Reports

Prognostic Value of Minnesota Multiphasic Personality Inventory-2 (MMPI-2) Profiles in Predicting Outcomes of Occipital Nerve Stimulation for Refractory Chronic Migraine: A Retrospective Bias-Corrected Multivariable Analysis

Review

作者: Naccarato, Alessia ; Varrassi, Giustino ; Viswanath, Omar ; Arcioni, Roberto ; Sarmi, Samah Said Al ; Leoni, Matteo Luigi Giuseppe ; Mercieri, Marco ; Cascella, Marco

Abstract:

Background:

Refractory chronic migraine (rCM) is characterized by debilitating headaches that do not respond adequately to conventional medical treatments, leaving patients severely disabled. In these rare cases, central cervical spinal cord stimulation or occipital nerve stimulation (ONS) may offer a potential therapeutic option. However, these techniques are not without risks, lack clear scientific evidence, and impose a significant economic burden. Therefore, it is crucial to identify parameters that can assist physicians in selecting appropriate candidates for implantation. This study aimed to investigate the role of psychological profiles in predicting outcomes for ONS in rCM patients.

Methods:

We conducted a retrospective analysis on rCM patients treated with ONS at a second-level neuromodulation university facility. These patients were refractory to conventional medical treatments, including onabotulinumtoxin-A injections (monoclonal antibodies targeting CGRP were not yet available). The NRS for migraine intensity, the number of monthly migraine attacks, and drug consumption were assessed at 6-month and 12-month follow-ups post-implant. Psychological profiles were evaluated prior to OCN using the Minnesota Multiphasic Personality Inventory-2 (MMPI-2). A multivariable logistic regression model was developed to predict ONS outcomes, incorporating MMPI-2 as a covariate. The model’s accuracy and performance were assessed through non-parametric bootstrap, calibration, and discrimination analyses.

Results:

Twenty-three rCM patients were analysed. ONS was able to significantly reduce the pain intensity, the number of headache attacks per month, and drug consumption compared to pre-treatment levels at both 6- and 12-month follow-ups. The final multivariable logistic model at 12 months showed that the MMPI-2 Depression score was independently and negatively associated with favourable outcomes following ONS (optimism-adjusted OR 0.52, 95% CI 0.21–0.77, p = 0.03). The ROC curve indicated high model sensitivity (AUC: 0.96, 95% CI: 0.88–0.98), and the calibration plot revealed a good fit, with some improvement needed in mid-range predicted probabilities.

Conclusion:

ONS significantly reduced pain intensity, headache frequency, and drug use at the 12-month follow-up compared to pre-treatment levels. The MMPI-2 Depression score was an independent predictor of ONS failure, highlighting the importance of comprehensive psychological assessments in patient selection for ONS.

405

项与 A型肉毒毒素相关的新闻（医药）

2025-08-07

·EINPresswire

DermAlign Medical Aesthetics Removes Wrinkles with Ease

DermAlign Medical Aesthetics now uses this minimally non-surgical cosmetic treatment called PDO Thread Lift as an alternative to the standard Surgical Facelift. LANGHORNE , PA, UNITED STATES, August 7, 2025 / EINPresswire.com / -- DermAlign Medical Aesthetics Removes Wrinkles with Ease August 7, 2025 DermAlign Medical Aesthetics based in Langhorne, Pa, would like to reach out to residents who may be in search of anti-aging medical spa treatments. This Med Spa offers a wide range of medical spa treatments with a special emphasis on wrinkle removal techniques. DermAlign Medical Aesthetics is a boutique med spa committed to providing exceptional cosmetic care using the latest non-surgical technologies. With a strong emphasis on natural beauty, safety, and personalized service, so whether you’re looking for Injectables, Micro-Needling, PDO Thread Lifting, Sexual Wellness, Medical Grade Weight Loss, Hair Restoration, PRP or the latest Hollywood Salmon Sperm PDRN DermAlign Medical Aesthetics has you covered. The Medical Staff at DermAlign Medical Aesthetics invests in over 100 Continuing Education hours per year ensuring that their patients receive the most advance & update treatments and thus allowing DermAlign Medical Aesthetic to be a leader in medical aesthetics field. Ekata Rushi PA-C, Founder of DermAlign Medical Aesthetics looks forward to providing quality, effective treatments to her patients. While DermAlign Medical Aesthetics mainly services the Mainline, Bryn Mawar, Bluebell, King of Prussia, New Hope, Bucks, Montgomery County PA. & Mercer & Hunterdon County NJ. “Men and women throughout the country as far as Alabama to Miami Fl. fly in to see Ekata Rushi PA-C. Patients can finally look and feel their best with the help of DermAlign Medical Aesthetics. Ekata Rushi PA-C at DermAlign Medical Aesthetics is a leading Aesthetic Medicine Physician Associate who offers her patients the latest in Wellness and Aesthetic solutions. Ekata specializes in the “30 minute nonsurgical face lift” using PDO Threads. Using the most advance Facelift techniques that she learned from the world leading plastic surgeons. So even if you’re looking for the best wrinkle removal treatments, DermAlign Med Spa utilizes many non-invasive techniques and treatments that can help remove wrinkles from the faces of our patients. One very popular option that is offered at the Med spa is the insertion of dermal fillers, which can help smooth out one’s skin and minimize the appearance of moderate to deep grooves and wrinkles. The spa uses clinically tested and proven dermal fillers from dependable producers like JUVÉDERM ® to fill in areas where the patient may have lost volume. The advanced dermal fillers used by Ekata Rushi PA-C are made to last a long time, and one can expect the effects to last up to years. While dermal fillers can boost the appearance of one’s skin on an immediate basis, it is still important to take care of one’s skin and protect it in order to lessen the effects of aging. DermAlign Medical Aesthetics offers its own Medical Grade Skin line solutions to help patients maintain the appearance of their skin. Ekata Rushi PA-C also offers her patients advice on how to avoid wrinkles. “Once Ekata Rushi PA-C gets you started on your custom anti-aging regimen you will begin to notice the benefits of injectables and Medical grade Skin products, you need to start looking at preventive skincare,” says Ekata. “Granted, you’re still going to age, so you can’t stop all wrinkles from forming. However, you can certainly work to lessen your risk of deep wrinkles and other signs of aging. The best way to prevent wrinkles is to minimize sun exposure and wear sunscreen daily. DermAlign Medical Aesthetics has an entire line of protective products that offer SPF protection. Some products are even tinted and blend in perfectly underneath your makeup. Schedule your anti-aging consultation at DermAlign Medical Aesthetics and take control of your wrinkles.” Ekata Rushi PA-C has over 14 years of Neurosurgical & Weight loss surgical and Emergency Medicine Experience. After over a decade of high-intensity medical & surgical care, she turned her attention to aesthetics, pursuing her passion for artistry and long-term patient care. Ekata lives in Newtown with her husband and two daughters and is deeply involved in the local community. At DermAlign, her mission is simple: to educate, empower, and enhance every patient’s natural beauty with safe, effective, and proven treatments. and is considered a leader in the cosmetic medicine industry. A number of Ekata patients have left excellent reviews of her work. One review on the DermAlign Medical Aesthetics GMB listing, from a patient named Edina “Omg I can’t say enough she is absolutely wonderful, check out my before and after pictures- also she called me in the evening and left me message to remind me of the aftercare needed, and the next day also to see how I was doing, you do not find anyone who will care enough to call and check on you anywhere !!! She is an amazing artist with her work; I will definitely be back also check her out on Instagram! " Another patient, Melissa “New Botox/Xeomin patient appointment today. The staff was very friendly & knowledgeable. Took their time to explain everything in detail. Didn’t feel rushed. I definitely will be returning.” Contact Information • DermAlign Medical Aesthetics • 320 Middletown Blvd, Ste 300, Langhorne, PA 19047, USA • info@dermalignmedspa.com • www.Dermalignmedspa.com EKATA RUSHI PA-C DERMALIGN MEDICAL ANESTHETICS INFO@DERMALIGNMEDSPA.COM Visit us on social media: Instagram Facebook YouTube TikTok Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-08-05

·EINPresswire

Spa Services Market Expected to Surpass $423.3 Billion by 2031 with a 17.3% CAGR From 2022-2031

Spa Services market was valued at $73,512.93 million in 2020, is projected to reach $423,253.69 million by 2031, grow a CAGR of 17.3% from 2022 to 2031. Medical spa is anticipated to be the fastest growing spa segment due to rapid advancements in medical field.” — Roshan Deshmukh WILMINGTON, NEW CASTLE, DE, UNITED STATES, August 5, 2025 / EINPresswire.com / -- Allied Market Research published a new report, titled, โ Spa Services Market Size, Share, Competitive Landscape and Trend Analysis Report, by Type and End User : Opportunities and Forecasts, 2022 - 2031โ. The report offers a detailed analysis of the top winning strategies, evolving market trends, market size and estimations, value chain, key investment pockets, drivers & opportunities, competitive landscape and regional landscape. The report is a useful source of information for new entrants, shareholders, frontrunners and shareholders in introducing necessary strategies for the future and taking essential steps to significantly strengthen and heighten their position in the market. Request Sample Copy of Report: https://www.alliedmarketresearch.com/request-sample/1502 Growth of the market is fostered by factors such as increased hectic lifestyles, rise in wellness tourism, surge in demand from teenagers, and improved standards of living. Moreover, increase in population of working women and rise in popularity of spa among male customers have supplemented the growth of global spa services market. However, scarce availability of skilled labor and lesser penetration in underdeveloped regions limit the market growth to a certain extent. Furthermore, the cost of employing skilled labor in the global spa services market is high, thereby adding to the operation costs incurred by the firms. The salon spa segment accounted for the largest market share of around 37.3% in 2020. Increase in disposable income among the middle-income class, affordable services, and innovative marketing strategies used by salons contribute to the growth of this segment. However, the highest CAGR of 17.7% is expected to be witnessed by the medical spa segment during the forecast period. Technological advancement in medical treatments such as laser technology, dermal fillers, cellfina, ultra therapy, and others drive the demand for medical spa. Hotel spa and destination spa are anticipated to witness notable growth during the forecast period, owing to massive investments in tourism infrastructure in Asia and Middle East. The global spa services market was dominated by Europe in 2020, owing to higher demand in Western European countries such as Germany, France, UK, and others. In addition, extensive demand arising from Eastern Europe countries due to rise in income of middle class customer groups has contributed significantly to the market. Moreover, Europe has greater number of established spas among other region. Asia-Pacific is the second largest region in the global spa services market owing to huge contribution by countries such as Japan and China, which are highly concentrated with mineral spa. LAMEA region is expected to witness the fastest growth of 17.6% during the forecast period; owing to rise in investments in tourism industry in countries such as Brazil and UAE.The tourism sector in Brazil has attained more proficiency and professionalism posing huge avenues for the global spa services market to expand in future. Moreover, urbanization and increasingly hectic work lifestyle are expected to continue to foster the demand for the market during the analysis period. Destination spa has also gained considerable popularity owing to rise in demand for traditional spas such as Ayurveda, Swedish, and Turkish massage. Growth in inbound & outbound tourism for the purpose of wellness drives the growth of destination spa service market. LIMITED-TIME OFFER - Buy Now & Get Exclusive Discount on this Report: https://www.alliedmarketresearch.com/checkout-final/048f77bfd3614da4287594e4142752fe Key companies profiled in this report includeFour Seasons Hotel Limited, Emirates Palace, Trailhead Spa, Jade Mountain Resort, Massage Envy Franchise LLC, Six Senses Hotels Resorts Spas, ClarinsDay Spa, Belmond Maroma Resort & Spa, LanserhofTegernsee Spa, and Gaia Retreat & Spa. ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐จ๐ ๐๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐๐ฌ ๐ข๐ง ๐ญ๐ก๐ ๐๐จ๐ซ๐ญ๐๐๐ฅ๐ ๐๐ฉ๐ ๐๐๐ซ๐ฏ๐ข๐๐๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฅ๐ฅ๐ง๐๐ฌ๐ฌ ๐๐ซ๐๐ง๐: The increasing focus on health and wellness has led to a growing demand for spa services. Consumers are looking for holistic approaches to health, and spas are seen as places that offer not only relaxation but also various wellness services. ๐๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ณ๐๐ญ๐ข๐จ๐ง ๐๐ง๐ ๐๐๐ซ๐ฌ๐จ๐ง๐๐ฅ๐ข๐ณ๐๐ญ๐ข๐จ๐ง: Spas were increasingly offering customized and personalized services to meet the unique needs and preferences of their clients. Tailoring treatments and experiences to individual requirements was becoming a key strategy for attracting and retaining customers. ๐๐๐๐ข๐๐๐ฅ ๐๐ฉ๐ ๐๐๐ซ๐ฏ๐ข๐๐๐ฌ: The popularity of medical spa services, which combine traditional spa treatments with medical procedures, was on the rise. These services often include procedures like laser hair removal, Botox injections, and other non-invasive cosmetic treatments. ๐๐ฎ๐ฑ๐ฎ๐ซ๐ฒ ๐๐ฉ๐ ๐๐ฑ๐ฉ๐๐ซ๐ข๐๐ง๐๐๐ฌ: High-end and luxury spa experiences were in demand, with consumers willing to pay a premium for exclusive treatments, luxurious facilities, and unique experiences. ๐๐ฅ๐จ๐๐๐ฅ ๐๐๐ฅ๐ฅ๐ง๐๐ฌ๐ฌ ๐๐จ๐ฎ๐ซ๐ข๐ฌ๐ฆ: The global wellness tourism industry was growing, and spas were benefiting from travelers seeking wellness-focused vacations. Destination spas, resorts, and hotels were incorporating spa services as part of their overall wellness offerings. ๐๐๐ฒ ๐๐๐ง๐๐๐ข๐ญ๐ฌ ๐จ๐ ๐ญ๐ก๐ ๐๐๐ฉ๐จ๐ซ๐ญ: โ The study provides an in-depth analysis of the global spa services market to elucidate the imminent investment pockets in the market. โ Current trends and future estimations are outlined in the report to determine the overall market potential and single out profitable trends to gain a stronger foothold in the market. โ The report provides information regarding drivers, restraints, and opportunities with a detailed impact analysis. โ Quantitative analysis of the current market and estimations from 2022 to 2031 are provided to showcase the financial competency of the market. โ Porterโs Five Forces model of the industry illustrates the potency of the buyers & suppliers. โ Value chain analysis provides a clear understanding of the roles performed by various intermediaries involved in the value chain. ๐๐๐๐ฌ๐จ๐ง ๐ญ๐จ ๐๐ฎ๐ฒ ๐๐ฉ๐ ๐๐๐ซ๐ฏ๐ข๐๐๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฉ๐จ๐ซ๐ญ: โ Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the global Spa Services Market. โ Highlights key business priorities in order to guide the companies to reform their business strategies and establish themselves in the wide geography. โ The key findings and recommendations highlight crucial progressive industry trends in the spa services industry, thereby allowing players to develop effective long-term strategies in order to garner their market revenue. โ Develop/modify business expansion plans by using substantial growth offering developed and emerging markets. โ Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those restraining the growth to a certain extent. โ Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to products, segmentation, and industry verticals. Enquiry About Report: https://www.alliedmarketresearch.com/purchase-enquiry/1502 ๐๐๐๐ ๐๐จ๐ซ๐ ๐๐ซ๐๐ง๐๐ข๐ง๐ "๐๐๐ ๐๐ฑ๐๐ฅ๐ฎ๐ฌ๐ข๐ฏ๐ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ: โข Massage Equipment Market is estimated to reach $15,083.6 million by 2031 https://www.alliedmarketresearch.com/massage-equipment-market-A16871 โข Electric Massagers Market Analysis and Projected huge Growth by 2027 https://www.alliedmarketresearch.com/electric-massagers-market-A07919 โข Massage Oil Market is Projected to Reach $8.1 Billion by 2031 https://www.alliedmarketresearch.com/massage-oil-market-A16859 โข Massage Guns Market Will Show An Increase Of By 2027, Report https://www.alliedmarketresearch.com/massage-guns-market-A07656 โข Massage Pillow Market by Manufacturer, Region, Type and Application Forecast to 2027 https://www.alliedmarketresearch.com/massage-pillow-market-A08073 โข Massage Chairs Market Analysis By Growth Rate, Opportunities and Forecast https://www.alliedmarketresearch.com/massage-chairs-market-A06988 โข Tea Tree Oil Market is projected to reach $ 59.5 Million https://www.alliedmarketresearch.com/tea-tree-oil-market David Correa Allied Market Research + + 1 800-792-5285 email us here Visit us on social media: LinkedIn Facebook YouTube X What Sets Us Apart ? - Allied Market Research Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-08-03

·Biotech前瞻

艾伯维2025年H1财报与PD-(L)1×VEGF双抗战略分析

点击蓝字关注我们本期看点在全球生物医药市场竞争日趋激烈的大背景下，艾伯维（AbbVie）于2025年上半年交出了一份兼具转型与成长信号的财报—在阿达木单抗（Humira，修美乐）专利悬崖持续冲击之下，其新一代免疫与神经科学产品快速崛起，展示了稳健的接棒潜力。与此同时，公司也在加速肿瘤免疫板块的重构布局，尤其开始对“PD-(L)1×VEGF”这一备受关注的双特异性抗体赛道释放出浓厚兴趣。本文将聚焦艾伯维2025年H1财务表现、核心产品走向与管线动态，深度解析其为何押注这一潜在“下一代免疫主力疗法”赛道，并置于全球竞争格局中观察其战略意图。本期内容01艾伯维丨2025H1财报分析02创新药物研发管线进展03PD-(L)1×VEGF双抗布局04总结与展望【01 艾伯维丨2025H1财报分析】公司整体财务表现营收与净利（2025 H1）: 艾伯维2025年上半年（1-6月）总营收约287.66亿美元，同比增长7.4%；归属母公司净利润约22.24亿美元（2024年同期27.39亿美元）。摊薄后每股收益为1.24美元（去年同期1.53美元）。各业务板块表现: 2025 H1，免疫学（Immunology）业务收入约138.95亿美元，同比增长12.6%；神经科学（Neuroscience）收入约49.65亿美元，同比增长20.3%；肿瘤学（Oncology）收入约33.09亿美元，同比增长4.2%；医疗美容（Aesthetics）收入约23.81亿美元，同比下降9.8%。其中免疫学板块的Skyrizi（利生奇珠单抗，IL-23抑制剂）和Rinvoq（乌帕替尼，选择性JAK抑制剂）是主要增长动力，均实现高双位数增长。主要产品销售情况Humira（阿达木单抗）: 由于专利到期及生物类似药竞争，上半年销售额仅约23.01亿美元，同比下降54.7%，呈持续下滑态势。Skyrizi（利生奇珠单抗）: 2025年H1销售约78.48亿美元，同比增长65.8%，增长强劲。Rinvoq（乌帕替尼）: 2025年H1销售约37.46亿美元，同比增长48.5%。Skyrizi和Rinvoq合计收入已超过Humira，成为公司最大的驱动产品。Vraylar（卡利拉嗪，精神分裂药物）: 2025年H1销售约16.65亿美元，同比增长13.5%。Botox（肉毒毒素，治疗型与美容型）：截至2025年Q2，Botox治疗型（Botox Therapeutic）季度收入9.28亿美元，同比增长14.1%；Botox美容型（Botox Cosmetic）收入6.92亿美元，同比仅略降5.0%。由此推算2025年H1 Botox治疗型约17.94亿美元，Botox美容型约12.48亿美元。Botox全线产品表现稳健，治疗型需求持续上升。02 创新药物研发管线进展接下来，我们具体来看艾伯维肿瘤和免疫领域管线进展。ADC： 2024年5月，艾伯维的c-Met ADC “Teliso-V”获批（抗晚期非小细胞肺癌）。公司另一款FRα靶点ADC（Elahere，索米妥昔单抗）上半年销售3.38亿美元，同比增长75.5%，显示出快速增长势头。艾伯维还推进多款新ADC，如双靶PSMA/STEAP1 ADC （ABBV-969），已进入1期临床。免疫检查点与双抗：公司自研的PD-1抗体布格利单抗（Budigalimab）处于Ⅱ期试验阶段；CCR8靶向抗体ABBV-514在1期试验中显示可耗竭肿瘤内调节性T细胞，正在与Budigalimab联用进行多项实体瘤临床研究。Epkinly（艾可瑞妥单抗，CD3×CD20双抗）自2023年获批上市，今年H1销售1.21亿美元，同比增长92.1%。外部合作与收购：上半年AbbVie积极进行BD活动，截至7月已完成约10笔交易，其中包括1月与先声药业合作开发GPRC5D/BCMA/CD3三特异抗体SIM0500；7月斥资19亿美元收购Amunix的三特异性T细胞衔接器（CD3/BCMA/CD38三抗，ISB-2001）。这些交易表明AbbVie正扩充三抗、ADC和其他创新靶向药物管线。【03 PD-(L)1×VEGF双抗布局】艾伯维公开表态对PD-(L)1×VEGF双抗感兴趣：艾伯维首席科学官于2025年二季度业绩电话会议上表示，公司注意到PD-(L)1×VEGF双抗赛道的进展，并明确提到“这一类别正在陆续披露多项数据，我们对此领域很感兴趣并在关注”。尽管艾伯维未公布具体的PD-(L)1×VEGF候选药物，但该表态表明了其浓厚兴趣。截至目前，艾伯维并未公开任何PD-(L)1×VEGF双抗在研产品。艾伯维表示将关注将双抗与其现有ADC相结合的潜力，但尚无已知联合研发或许可合作公告。PD-(L)1×VEGF双抗集成了免疫检查点阻断和抗血管生成机制，被视为“下一代”肿瘤免疫基础治疗药物，具备成为千亿美元市场基石药物的潜力。艾伯维拥有多款肿瘤免疫和ADC产品（如Teliso-V、Elahere、Epkinly等）及PD-1单抗Budigalimab。公司认为，新双抗若与其ADC管线联合使用，可在多种适应症中发挥协同效应。例如，早期研究中Summit/辉瑞就计划将PD-1×VEGF双抗Ivonescimab与多种ADC联合测试。艾伯维布局PD-(L)1×VEGF的决策正是基于希望与其多元化抗肿瘤药物组合产生增效作用。行业趋势与竞争格局：目前全球已有多家公司研发PD-(L)1×VEGF双抗，并涌现大量大额交易。国际巨头，如默沙东、辉瑞等纷纷通过授权或并购等方式大力布局此领域。研究机构普遍认为，PD-(L)1×VEGF类双抗可能成为肿瘤免疫治疗的新主流方案。在此背景下，艾伯维加入该领域可补齐产品线空白，并抢占未来市场先机。04 总结与展望综上所述，艾伯维在2025年上半年展现出强劲的业务韧性与转型决心：Skyrizi 和 Rinvoq 持续高增长，带动免疫板块超越 Humira 成为新的业绩支柱；神经科学和ADC产品线同样表现亮眼。与此同时，公司在肿瘤免疫领域加速拓展布局，明确表达对PD-(L)1×VEGF双抗的战略兴趣，意在借此补强其免疫治疗矩阵、提升管线协同效益，并抢占下一轮肿瘤免疫主流治疗窗口。面对全球竞争者在该赛道的迅速推进，艾伯维的这一表态不仅释放出其研发战略的前瞻性信号，也预示着下一阶段大分子双抗布局或将迎来新的资本与创新热潮。 ★

财报抗体药物偶联物免疫疗法专利到期生物类似药

100 项与 A型肉毒毒素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08957	A型肉毒毒素	M03AX01	DB00083

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
咀嚼肌肥大	中国	Allergan, Inc.	2024-06-03
肌张力失调	美国	AbbVie, Inc.	2022-08-22
神经源性逼尿肌过度活动	美国	AbbVie, Inc.	2022-08-22
发声困难	日本	GSK Plc	2018-05-25
膀胱功能障碍	美国	AbbVie, Inc.	2017-04-04
外眦皱纹	美国	AbbVie, Inc.	2013-09-11
上下肢痉挛	美国	AbbVie, Inc.	2010-03-09
马蹄状畸形	日本	Allergan, Inc.	2009-01-21
多汗症	日本	Allergan, Inc.	2009-01-21
皮肤疾病	日本	Allergan, Inc.	2009-01-21
神经性膀胱功能障碍	日本	Allergan, Inc.	2009-01-21
原发性颈性肌张力障碍	日本	GSK Plc	2005-10-03
肌肉痉挛	-	Genesis Healthcare, Inc.	2005-10-03
肌痛性痉挛	中国	Allergan Pharmaceuticals Ireland ULC	2003-04-22
斜颈	日本	GSK Plc	2000-06-20
马蹄足	日本	GSK Plc	2000-02-23
面肌痉挛	日本	GSK Plc	2000-01-18
眼睑痉挛	澳大利亚	AbbVie Pty Ltd.	1999-07-09
颈肌张力障碍	澳大利亚	AbbVie Pty Ltd.	1999-07-09
鱼尾纹	澳大利亚	AbbVie Pty Ltd.	1999-07-09

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
先兆偏头痛	临床3期	美国	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	加拿大	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	捷克	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	德国	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	以色列	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	波兰	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	西班牙	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	瑞典	AbbVie, Inc.	2021-11-05
先兆偏头痛	临床3期	英国	AbbVie, Inc.	2021-11-05
无先兆偏头痛	临床3期	美国	AbbVie, Inc.	2021-11-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06218251 (UFL BOND 974, CTgov)	临床4期	面部皱纹	100	BOTOX	願齋壓獵夢簾膚蓋選獵 = 網製遞膚簾鹹夢壓範鬱願築鏇構齋鑰鹹顧選範 (蓋構艱壓壓膚積餘選製, 淵築壓鬱獵構糧膚鬱鹽 ~ 廠糧顧觸築鬱襯築糧積) 更多	-	2025-08-06
NCT04609020 (CTgov)	临床4期	皮肤疾病 \| 皮肤起皱	64	Lidocaine+BOTOX	鹽繭顧願鏇餘憲艱衊選(壓鬱鹽網鑰網簾鑰鹹網) = 膚膚膚繭窪襯齋鑰顧構壓顧廠鏇遞網壓製膚積 (製蓋獵廠願壓壓蓋構製, 23.61) 更多	-	2025-06-17
NCT04965311 (CTgov)	临床2期	胰腺瘘 \| 胰腺癌	4	Botulinum Toxin Type A	鑰衊繭鑰壓鬱廠網壓積 = 蓋範齋鬱願壓選構鹽夢選夢鏇築膚構襯製顧艱 (鹹構鹹糧艱醖膚廠網壓, 製廠獵艱憲範鏇鏇製鏇 ~ 壓遞餘願憲艱糧構網積) 更多	-	2025-05-13
NCT04073303 (CTgov)	临床3期	-	377	Placebo	憲餘襯餘觸顧築衊襯夢 = 齋繭廠範齋簾製糧衊顧顧鏇廠淵壓衊製鑰鑰淵 (鏇網鹽製壓醖壓膚憲醖, 糧積獵觸窪選鬱構糧網 ~ 廠選襯壓壓壓糧築選繭) 更多	-	2025-05-06
NCT04171531 (MUSA, CTgov)	临床3期	压力性尿失禁 \| 急迫性尿失禁	150	Mid-urethral sling	憲窪願壓網製構鬱膚繭(範窪窪廠獵願獵醖遞鏇) = 鹽淵膚餘願鑰齋鏇簾憲顧鏇壓衊網構繭選構齋 (醖窪積糧餘衊選鬱鹹鹽, 願簾齋艱築窪顧艱選膚 ~ 繭壓範憲簾積餘觸網憲) 更多	-	2025-03-20
NCT05308979 (CTgov)	临床4期	尿频 \| 急迫性尿失禁 \| 膀胱过度活动症综合征	116	OnabotulinumtoxinA 100 UNT [Botox] (1 Injection Site)	壓膚構積窪膚淵艱淵網(製積齋觸憲鹽積築餘醖) = 艱膚遞製齋遞蓋獵鑰觸衊選醖簾衊鹹蓋顧餘築 (蓋鏇遞鬱糧構獵築積顧, 26.25) 更多	-	2025-02-14
NCT05308979 (CTgov)	临床4期	尿频 \| 急迫性尿失禁 \| 膀胱过度活动症综合征	116	OnabotulinumtoxinA 100 UNT [Botox] (10 Injection Sites)	壓膚構積窪膚淵艱淵網(製積齋觸憲鹽積築餘醖) = 網衊憲夢窪鹽窪選艱餘衊選醖簾衊鹹蓋顧餘築 (蓋鏇遞鬱糧構獵築積顧, 24.92) 更多	-	2025-02-14
NCT06080438 (CTgov)	临床4期	多泪 \| 眼睑痉挛	2	Botulinum toxin	積範蓋糧簾餘醖艱鏇齋(窪蓋觸網衊範獵範膚淵) = 繭鏇夢鏇襯夢遞憲鏇齋築廠鬱鑰鹽積壓製製廠 (餘製糧艱蓋餘製構艱製, 0.69) 更多	-	2024-12-05
NCT05134649 (CTgov)	临床3期	颈阔肌突出	292	OnabotulinumtoxinA	鹹廠鑰簾夢膚窪醖遞鬱(鹹夢鬱獵網顧顧鏇窪艱) = 餘製蓋鹽網遞範選艱簾製簾構膚築艱鏇築醖夢 (夢選壓獵窪鬱艱廠膚獵, 夢蓋鏇選窪選艱壓範窪 ~ 構網餘鹽艱繭築觸壓築) 更多	-	2024-12-05
NCT03456154 (Pubmed \| J Dent)	临床4期	夜磨牙症 \| 肌痛	-	botulinum toxin-a (Occlusal splint)	獵膚鹽壓蓋襯構鏇淵構(選夢壓糧膚夢醖選構選): OR = 0.29 (95% CI, 0.11 ~ 0.82)	积极	2024-12-01
NCT03456154 (Pubmed \| J Dent)	临床4期	夜磨牙症 \| 肌痛	-	Botulinum toxin-A	獵膚鹽壓蓋襯構鏇淵構(選夢壓糧膚夢醖選構選): OR = 0.29 (95% CI, 0.11 ~ 0.82)	积极	2024-12-01
NCT04949399 (CTgov)	临床3期	颈阔肌突出	408	Placebo (Placebo)	艱製觸艱獵廠獵艱膚鹹 = 鑰築鬱艱鹽築製鏇淵築鬱鹹繭齋獵鏇壓範糧觸 (範夢獵餘夢艱積壓廠觸, 壓襯齋網遞範網鹽顧製 ~ 簾遞網築齋鬱膚繭齋網) 更多	-	2024-11-20
NCT04949399 (CTgov)	临床3期	颈阔肌突出	408	OnabotulinumtoxinA (BOTOX)	艱製觸艱獵廠獵艱膚鹹 = 鹹顧襯鏇廠鏇餘遞衊觸鬱鹹繭齋獵鏇壓範糧觸 (範夢獵餘夢艱積壓廠觸, 餘淵糧鏇鏇顧顧觸鬱糧 ~ 遞鏇網膚夢觸壓構壓鑰) 更多	-	2024-11-20